Calquence is under clinical development by AstraZeneca and currently in Phase II for Graft Versus Host Disease (GVHD).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Steroid-refractory acute graft-versus-host disease is a serious condition that ... This procedure is often performed as part of treatment for certain types of blood cancers, blood disorders ...

Sergio A. Giralt, MD, discusses how the pathophysiology of chronic graft-vs-host disease involves complex immune dysregulation, with CSF1R playing a crucial role in driving the differentiation of ...

China's top drug regulator has recently approved the nation's first stem cell therapy to treat a type of complication ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for ...

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

Steroid-refractory acute graft-versus-host disease is a serious condition that can occur as a complication of allogeneic ... This procedure is often performed as part of treatment for certain types of ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

INR:9175. lucky guessing number Novartis JAK inhibitor treatment for graft-versus-host disease reaches Phase 3 clinical endpoint DMD innovative therapy rece ...